AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
AnaptysBio Inc (NASDAQ: ANAB ), a clinical-stage biotechnology company focused on immunology therapeutics, has sold its royalty interest on future global net sales of Zejula (Niraparib) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million . GSK Plc''s (NYSE: GSK ) Zejula is indicated as monotherapy for the maintenance treatment of advanced ovarian cancer. AnaptysBio has … Full story available on Benzinga.com
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
AnaptysBio Inc (NASDAQ: ANAB ), a clinical-stage biotechnology company focused on immunology therapeutics, has sold its royalty interest on future global net sales of Zejula (Niraparib) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million . GSK Plc''s (NYSE: GSK ) Zejula is indicated as monotherapy for the maintenance treatment of advanced ovarian cancer. AnaptysBio has … Full story available on Benzinga.com